about
Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymesControl of MT1-MMP transport by atypical PKC during breast-cancer progression.A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.Variable use of endoscopic haemostasis in the management of bleeding peptic ulcersRegorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma.Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdomUpdate on imatinib for gastrointestinal stromal tumors: duration of treatment.aPKC Inhibition by Par3 CR3 Flanking Regions Controls Substrate Access and Underpins Apical-Junctional Polarization.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Protein kinase C intervention: the state of play.Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.Fistulation as a complication of intra-abdominal soft-tissue sarcomas; a case series.Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.PKC and the control of localized signal dynamics.Atypical protein kinase Cι as a human oncogene and therapeutic target.Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.Nonsurgical oncological management of cancer pain.Targeting protein kinase C in sarcoma.Evolving adoptive cellular therapies in urological malignancies.mTORC2 targets AGC kinases through Sin1-dependent recruitment.Binding of dynein intermediate chain 2 to paxillin controls focal adhesion dynamics and migration.Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.Prostate cancers that ‘Wnt’ respond to abirateroneA Cancer-Associated Mutation in Atypical Protein Kinase C Occurs in a Substrate-Specific Recruitment MotifPDT with a Glucose-Conjugated Chlorin for GIST--LetterFunctional implications of assigned, assumed and assembled PKC structuresExperience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancerRenal tubular acidosis due to oxaliplatin
P50
Q27684030-8532287E-96A1-4721-AE06-AAC2E7874505Q30577989-65492450-7D57-441A-B732-96B2754C835FQ34278435-1A88BE8A-D111-4105-B6B3-F2751EFEA3B2Q35514470-ECE57C59-D269-400D-84AD-D2DB2C331804Q35519994-93769AE1-5A9D-48B7-8444-7DA1C550B67FQ35544697-9F3081FD-31FE-474A-B00F-45D4CAD30567Q36731032-E961108F-7F24-4EBD-81F3-059ED5231931Q37075052-3B48D428-B7E9-4CF9-A04A-3E68C2256160Q37204172-4528E964-6A24-4754-B542-4CC07F6A200EQ37330372-66596018-D30A-4D92-8E8F-239EFF7B7545Q37398291-CD3E6EE3-EC8F-4AB4-91E4-53D06E027897Q37402813-1FD2ADD3-D068-4B77-A99D-A328DF7786F7Q37463239-1C97AE5E-599D-4B2B-8FD8-73D9AA479BA2Q37537542-8E3C25E2-0AD6-4222-9F11-AC85241ED5C9Q37679691-7203D954-0B83-403F-A588-269580105876Q38162656-2C591D52-F640-4AAA-AD1F-0B8438E6A61AQ38197031-02B247B6-AD1C-4789-8D97-F3CCB5FCC4ABQ38199927-D26B382A-4D46-44EA-B9E0-FECCC90A2762Q38277058-A6CF7F65-6379-4CB0-A1F5-47C847B5DAAEQ39359095-41E3E95D-4E63-4D32-AE7F-8FA9B986A648Q39497163-12C55CC5-630B-4499-9113-81380E0DA7E2Q46113222-882AEC2B-D52D-438C-83EF-2D06371C889FQ47725386-127917BE-5E34-4E8F-82C1-29C03F497533Q47974667-EDCC644A-DCA2-4E86-A13D-82DBA4F3A8C8Q57693838-94DCAF59-BEBF-4975-807A-BE697F14BA1AQ58173395-75CF881F-2A92-4534-8F95-F0409DA4279FQ60997826-DA9596A8-5BA9-42D1-B914-D15EB17B768BQ60997827-19F57729-02AA-44EA-A1ED-F0B433DABACBQ60997828-323DC97D-441C-4A0B-BE54-477BCC80A320Q60997829-86E725FA-B2FF-44D8-9F45-C86656CC1FF3
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Linch
@ast
Mark Linch
@en
Mark Linch
@es
Mark Linch
@nl
type
label
Mark Linch
@ast
Mark Linch
@en
Mark Linch
@es
Mark Linch
@nl
prefLabel
Mark Linch
@ast
Mark Linch
@en
Mark Linch
@es
Mark Linch
@nl
P106
P21
P31
P496
0000-0003-2305-8486